Vaccinogen Announces that Swissmedic Health Authorities Granted Its Swiss Distribution Partner, ProVaccine, Permission to Export Biopsies and Import Vaccines on behalf of Vaccinogen.
October 22, 2009
Vaccinogen Announces New Relationship with CRO Clinipace Worldwide
July 24, 2009
Vaccinogen Announces Submission of Final Documentation to Swissmedic for Pivotal Review of OncoVAX®
July 17, 2009
May 15, 2009
April 20, 2009
Vaccinogen Announces That Michael G. Hanna, Jr., Ph.D. is Scheduled to Speak at the Barcelona Vaccine Forum 2009 in June 2009
March 1, 2009
Vaccinogen Announces Addition of David Hatt to its Board of Directors
November 14, 2008
November 13, 2008
OncoVAX, Other Vaccines Provide Hope for Colorectal Cancer Treatment, Prevention
June 4, 2008
Thomson Reuters' Pharma Matters highlights Vaccinogen’s OncoVAX® as “One to Watch”
May 7, 2008
February 27, 2008
Vaccinogen's New Anti-Cancer Vaccine Commercially Available in Europe This Year
February 11, 2008
Cancer Pioneer Reaches Key Agreement On Colon Cancer Drug OncoVAX®
November 10, 2007
Vaccinogen Announces the Successful Acquisition of Key Management and Staff
November 4, 2007
Vaccinogen Announces Successful Acquisition of cGMP Manufacturing Facility
November 3, 2007
Vaccinogen Announces Completion of its Initial Capitalization Plan
October 1, 2007
Vaccinogen Announces Formation of Company
July 19, 2006
FDA Grants Special Protocol Assessment
July, 2006
FDA Grants Intracel “Fast Track ” Designation for the Development of Its Colon Cancer Vaccine
Frederick, MD USA/Baar, Switzerland – November 14, 2008 - Vaccinogen is pleased to announce that ProVaccine, its Swiss-based distribution partner for OncoVAX®, has been granted permission to export biopsies and import vaccines for OncoVAX® in Switzerland.
“We are delighted but not surprised to receive this good news for both Vaccinogen and ProVaccine.” says Michael G. Hanna, Jr., Ph.D., Vaccinogen’s Chairman & CEO. “Our partners at ProVaccine enjoy an excellent relationship with Swissmedic as a result of their commitment to excellence.”
Vaccinogen already has established in Neuchâtel, Switzerland, a preparation laboratory for the final preparation of the vaccines and doctor’s can apply the vaccine under patient named use to Swiss and foreign patients on a self-pay basis. The decision by Swiss Medic to permit ProVaccine to import OncoVAX® enables ProVaccine to represent OncoVAX® under its own name. The process leading up to this decision started in December 2007 and involved a thorough inspection of the ProVaccine staff, policies, procedures and command of OncoVAX®.
Establishing ProVaccine as the importer for OncoVAX® is the final step towards
granting OncoVAX® full registration status, thus paving the way for Swiss insurance
reimbursement for Swiss patients and opportunities for certain other countries to adopt
the Swiss registration for their respective countries. Final OncoVAX® registration
decision by Swiss Medic is expected in 2009.
About OncoVAX®
OncoVAX® immunotherapy is based on a decades-long attempt by scientists to transform the body’s immune response and its long-term memory to prevent the return of disease years after surgery. Such an approach has already been successful in preventing a number of infectious diseases.
About Vaccinogen
About Vaccinogen
Vaccinogen is a biopharmaceutical company that develops and commercializes cancer vaccines and other immunotherapeutic products – Turning Cancer on Itself™. Based in Frederick, MD, the company has a portfolio of product candidates for the treatment of cancer, infectious disease, autoimmune, anti-inflammatory diseases and fully human monoclonal antibodies in various stages of clinical development.
www.vaccinogeninc.com
Vaccinogen’s online press kit: www.vaccinogeninc.com/press_kit.cfm
Contact:
Andrew L. Tussing
Vaccinogen
atussing@vaccinogeninc.com
301-668-8400